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Abstract 
Cholangiocarcinomas (CCAs) are tumors with a dismal prognosis. Early diagnosis is 
a key challenge because of the lack of specific symptoms, and the curability rate is 
low due to the difficulty in achieving a radical resection and the intrinsic 
chemoresistance of CCA cells. Non-coding RNAs (ncRNAs) are transcripts that are 
not translated into proteins but exert their functional role by regulating the 
transcription and translation of other genes. The discovery of the first ncRNA dates 
back to 1993 when the microRNA (miRNA) lin-4 was discovered in Caenorhabditis 
elegans. Only 10 years later miRNAs were shown to play an oncogenic role in 
cancer cells and within 20 years miRNA therapeutics were tested in humans. Here 
we review the latest evidence for a role for ncRNAs in CCA and discuss the promise 
and challenges associated with the introduction of ncRNAs into clinical practice.  
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Main concepts and learning points: 
• Cholangiocarcinoma (CCA) is a rare and heterogenous tumor entity with a 
poor prognosis and limited therapeutic options. 
• Non-coding RNAs (ncRNAs) are classified according to their length into small 
(18 to 200 nucleotides) and long (>200 nucleotides) RNAs, and according to 
their function into housekeeping (e.g. ribosomal RNA and transfer RNA) and 
regulatory (e.g. microRNA, piwi-interacting RNA, long non-coding RNA) 
RNAs. 
• Dysregulation of ncRNAs has been implicated in cholangiocarcinogenesis, 
tumor progression and chemotherapy resistance. 
• microRNAs have been isolated and characterized in both the primary tumor 
tissue and bodily fluids (serum, plasma, urine, bile) of patients with CCA. 
• microRNAs hold the potential to be introduced into the clinic as diagnostic, 
prognostic and predictive biomarkers for CCA. Efforts to design therapeutics 
that deregulate ncRNAs are ongoing. 
 
 
 
Overview of cholangiocarcinoma 
Cholangiocarcinoma (CCA) is a rare solid tumor arising from the biliary tree. CCAs 
are classified as intrahepatic (iCCA), perihilar (pCCA) or distal (dCCA), according to 
their anatomical location within the biliary tree 1-5, and each subtype has unique 
epidemiological, clinical and biological features. The incidence of CCA varies greatly 
across the world, reflecting different environmental and genetic risk factors, and has 
steadily increased over the last four decades, particularly that of iCCA6. In the 
Western world, the incidence of CCA varies from 0.3 to 3.5 cases per 100,000, 
whereas in Thailand, where it peaks, there are 80 cases per 100,0007. Primary 
sclerosing cholangitis (PSC) is the most established predisposing factor to CCA in 
Western countries; while hepatobiliary fluke infestation and hepatolithiasis are well-
documented risk factors in Eastern countries8. Late diagnosis and resistance to 
conventional therapies largely account for an almost invariably dismal prognosis. 
Surgical resection followed by adjuvant therapy is the only curative approach 
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recommended by international practice guidelines9. However, these are feasible in 
<30% of cases, and even in these cases 5-year overall survival (OS) is disappointing 
ranging from 20% to 40%10. Most patients present with unresectable advanced 
disease at diagnosis and can only be offered palliative treatment, with an associated 
median OS of <12 months11-12. Huge efforts are being made by the research 
community to discover novel therapeutics for CCA, along with tumor biomarkers that 
could aid diagnosis, predict treatment efficacy or improve prognostication. In the past 
few years, high-throughput technologies have enabled extensive genome, exome, 
and transcriptome sequencing unveiling, amongst other things, the regulatory 
potential of non-coding RNA (ncRNA)13. In this article we review the role of ncRNAs 
in cholangiocarcinogenesis and tumor progression, as well as the potential for 
ncRNAs to be incorporated into the clinical management of CCA patients. 
 
 
The genomic landscape of cholangiocarcinoma 
The clinical heterogeneity of CCA is reflected also at the molecular level. Genome 
profiling studies have identified numerous genetic aberrations that affect metabolic, 
mitogenic, chromatin remodeling, and DNA repair signaling pathways. Notably, the 
mutational spectrum of CCA has been reported to vary according to the anatomical 
subtype and aetiology. Isocitrate dehydrogenase 1 or 2 (IDH 1/2) mutations (4.9-
36%), fibroblast growth factor receptor 1-3 (FGFR 1-3) fusions, mutations and 
amplifications (11-45%), and BAP1 mutations (13%) occurr more frequently in iCCA; 
while KRAS mutations (8.3-42%), SMAD4 mutations (21%), and ERBB2/3 
amplifications (11-17%) are observed more commonly in extrahepatic CCA14. 
Regarding aetiology, liver fluke-driven CCA are enriched in ERBB2 amplifications 
and TP53 mutations; by contrast, non-liver fluke associated CCA present high copy-
number alterations and PD-1/PD-L2 expression,  or  epigenetic  mutations  (IDH1/2, 
BAP1)  and FGFR/PRKA-related gene rearrangement15-16. 
Given the considerable genetic diversity of CCA with low penetrance driver 
aberrations and dependance on multiple pathways, several attempts have made to 
molecularly subtyping CCA to get clinical useful information. In a collaborative effort 
by the International Cancer Genome Consortium an integrated genomic, epigenomic 
and transcriptomic analysis was performed on 489 CCAs from 10 countries leading 
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to the identification of 4 subgroups, each harboring distinct genetic, epigenetic and 
clinicopathologic features16.  
Notably, this molecular clustering, thought to reflect the multifactorial interplay 
between genetics, epigenetics and environment in cholangiocarcinogenesis, displays 
a prognostic vaule (cluster 3 and 4 have a better prognosis than cluster 1 and 2) and 
provides an in-depth characterization of CCA beyond anatomical site (e.g. iCCA are 
splitting across all 4 cluster and the subtyping can be reproduced within each 
anatomical location separately). 
Moreover, through multiplatform analyses (somatic mutations, DNA methylation, 
copy number, RNA expression) in a set of predominantly iCCA, The Cancer Genome 
Atlas group identified a molecularly distinct subtype of IDH-mutant CCA, displaying 
increased mithocondrial gene expression and DNA copy number and low chromatin 
modifier gene expression17. Interestingly, in the same study, the authors found 21 
lncRNAs that correlated with the chromatin modifier signature, whereas one miRNA 
(miR-194-5p) was upregulated in the IDH-mutant subtype and negatively associated 
with the chromatin modifier siganture. 
 
 
Non-coding RNAs 
Although at least 80% of the human genome is biologically active, only roughly 3% is 
transcribed into protein-coding mRNAs18. The near totality of it, once termed “junk”, 
is now known to be made up of RNA that is transcribed but not translated into 
proteins, the so-called ncRNA. This term encompasses several classes of transcripts 
that can be classified according to their length into small (18 to 200 nucleotides) and 
long (>200 nucleotides) RNAs, and according to their function into housekeeping 
(e.g. ribosomal RNA and transfer RNA) and regulatory (e.g. microRNA, piwi-
interacting RNA, long non-coding RNA) RNAs19. Non-coding RNAs are master 
regulators of transcription, transcript stability, and translation of protein-coding 
transcripts, with roles in both physiological processes and human diseases, including 
cancer. Among ncRNAs, microRNAs (miRNAs), transcripts of 18 to 24 nucleotides in 
length, are the most extensively studied. As a result of conserved seed pairing over 
just 7 or 8 bases on multiple mRNAs, a single miRNA has the potential to target 
thousands of genes20. miRNAs have been traditionally regarded as negative 
regulators of gene expression that, upon binding to the 3’ untranslated region of a 
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target mRNA, leads to its translational inhibition or degradation, thus downregulating 
the final protein output of protein-coding genes. However, over recent years, new 
insights into miRNA properties have emerged that are unveiling much broader 
regulatory functions than initially thought. Indeed, they were shown to target various 
non-canonical sites such as DNA promoter regions, RNA 5’ untranslated region, 
other ncRNAs and proteins. Moreover, miRNAs can upregulate protein translational 
both directly, via recruitment of protein complexes, and indirectly, unleashing the 
translation repression exterted by inhibitory proteins. Again, there is also evidence 
that miRNAs can affect the Toll-like receptor signalling and downstream pathways 
(e.g. nuclear factor-kB pathway) through an agonist effect on Toll-like receptors21.  
With regards to their link with cancer, miRNAs have been shown to be deregulated in 
almost all human tumor types and to affect several steps of carcinogenesis by acting 
either as oncogenes or tumor suppressors22-23. More interestingly, signatures 
consisting of aberrantly expressed miRNAs have been found to have specific 
diagnostic and prognostic value13. On this basis, miRNAs have been regarded as 
promising tools for improving the management of cancer patients. Next, we discuss 
the involvement of ncRNAs in the regulation of cancer hallmarks, and the challenges 
associated with translating these findings into the clinic (Figure 1). 
  
 
Role of miRNAs in cholangiocarcinogenesis 
miRNA dysregulation has been shown to affect almost all CCA hallmarks, ranging 
from sustained cell proliferation to cancer-related inflammation (Tables 1 & 2). 
 
Sustaining proliferative signaling 
The earliest evidence for the role of ncRNAs in cholangiocarcinogenesis came from 
a study by Meng et al.24, in which they found CCA cells had deregulated miRNA 
expression and that miR-21 had a predominant role in enhancing tumor cell growth. 
miR-21 overexpression was confirmed in independent cohorts of human primary 
CCA patients and its oncogenic role was linked, at least partially, to the inhibition of 
programmed cell death 4 and TIMP metallopeptidase inhibitor 3 expression25. miR-
26a has also been shown to be up-regulated in human CCA, leading to increased 
proliferation of CCA cells via activation of beta-catenin-dependent genes26. It is 
interesting to note that miR-26 was found to be an oncosuppressor in hepatocellular 
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carcinoma (HCC), the other form of primary liver cancer27, underlining the 
peculiarities of tissue-dependent miRNA expression. More recent evidence supports 
an oncogenic role for miR-191 and miR-181c in CCA, specifically their ability to 
sustain tumor growth and drive cancer aggressiveness28-29. It is likely that several 
miRNAs with oncogeneic and oncosuppressive properties interplay within cancer 
cells to promote a given phenotype. For instance, Olaru and colleagues identified a 
role for miR-494 as a negative regulator of cancer cell growth, by showing that miR-
494 expression is down-regulated in CCA samples and that it has the ability to inhibit 
progression through the cell cycle30. Moreover, miRNAs often affect a cancer cell 
phenotype as a result of their ability to modulate multiple key players. For example, 
the expression of miR-494 induces a global deregulation of genes involved in 
progression through the cell cycle including cyclin dependent kinase 6, cyclin 
dependent kinase 4, cyclin D1, cyclin E2, histone deacetylase 1, RB transcriptional 
corepressor 1, polo-like kinase 1, pituitary tumor-transforming 1, cyclin B1, cyclin 
dependent kinase 2, and DNA topoisomerase II alpha31.  
 
Resisting cell death 
Protection from cell death is another process in which miRNAs are involved. 
Apoptotic signaling pathways seem to be regulated by a combination of miRNAs with 
oncosuppressive or oncogenic functions. These include the oncosuppressive miR-
29, whose loss in CCA is associated with an increase in the abundance of the anti-
apoptotic protein myeloid cell leukemia sequence 132, and the oncogenic miR-25, 
whose high expression in CCA cells is responsible for resistance to TNF-related 
apoptosis-inducing ligand (TRAIL)-induced apoptosis33.  
 
Activating invasion and metastasis 
It was recently reported that changes in miRNA expression induce the epithelial-
mesenchymal transition (EMT), a process whereby epithelial cells lose polarity and 
cell-to-cell adhesion in order to acquire invasiveness and migratory capabilities like 
mesenchymal elements. A study by Oishi et al., which employed integrative pathway 
analysis, linked miR-200c signaling to the EMT in a subtype of iCCA with stem-like 
gene expression features, providing an explanation as to why this subtype is 
clinically aggressive34. Overexpression of miR-21 was also associated with typical 
EMT features such as a low level of E-cadherin and high levels of N-cadherin and 
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vimentin, suggesting how a single miRNA can sustain tumor progression by acting 
on different pathways35-36. In addition, it has been shown that miRNAs involved in the 
regulation of EMT can increase the metastatic behavior of human CCA cells37-39. 
 
Tumor-promoting inflammation  
Chronic biliary tract inflammation is thought to be the most robust factor to drive 
cholangiocarcinogenesis. CCA often arises in the setting of conditions such as PSC, 
hepatolithiasis, choledochal cysts and liver fluke infestations. Moreover, the 
inflammation-associated cytokine Interleukin-6 (IL-6) is increased in both the biliary 
tract and the systemic circulation of CCA patients, where it promotes neoplastic 
growth and survival through autocrine and/or paracrine mitogenic signals40-41. 
Persistent IL-6 stimulation can alter miRNA expression both in vitro and in vivo and 
the resulting up-regulation of let-7 contributes to IL-6-dependent signal transducer 
and activator of transcription 3 (STAT-3) survival signaling in malignant human 
cholangiocytes42-43. In addition, IL-6 can favor CCA growth by methylation-
dependent regulation of miR-370 and associated targets such as the transcript of the 
oncogene mitogen-activated protein kinase kinase kinase 8 (MAP3K8)44. Enforced 
IL-6 expression can negatively modulate miR-148a and miR-152 in human CCA 
cells, leading to an increase in the level of DNA methyltransferase 1 and silencing of 
critical tumor suppressor genes such as Ras association domain family member 1 
(RASSF1) and cyclin dependent kinase inhibitor 2α (CDKN2A, also known as 
p16INK4a)45. Distinct miRNA signatures were also identified in Opisthorchis viverrini-
driven CCA, suggestive of the effect of inflammation on miRNAs46-47. This evidence 
strengthens the biological basis for the interplay between an inflammatory 
microenvironment, epigenetics and molecular events involved in 
cholangiocarcinogenesis, along with providing a rationale for targeting miRNAs that 
control the inflammatory response. 
 
Microenvironment 
The tumor microenvironment is a complex network made up of both cancer cells and 
reactive peritumoral stroma, the latter being enriched for various host cells including 
cancer-associated fibroblasts (CAF), endothelial cells, immune cells and tumor-
associated macrophages48-49. Tumor-reactive stroma has been hypothesized to be a 
pivotal driver of CCA initiation and progression by affecting the behavior of cancer 
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cells. The loss of miR-15 was found to be specific for CCA-associated fibroblasts 
when compared to skin-derived fibroblasts, suggesting a key role for ncRNAs in 
driving the transformation of stromal cells into CAFs that have a functional role in 
promoting cancer growth and chemoresistance50. miRNAs have lately emerged as 
novel players in the intercellular communication network that exists between different 
cell types in the tumor microenvironment. miRNAs are released from donor cells in 
extracellular vescicles (EVs), and can induce phenotypic and functional changes in 
recipient target cells. Evidence suggests that the ncRNA within EVs released from 
non-malignant and malignant cells is different, and that tumor-specific EVs contain 
short or long ncRNAs that can modulate how cells respond to hypoxia, control their 
growth and respond to drugs51-52 . Exosomes, a subtype of EV, can be found in the 
bile of rat models and influence intracellular signaling mechanisms and 
cholangiocyte proliferation via interaction with cholangiocyte cilia53. Furthermore, 
miRNA-loaded vesicles derived from myofibroblasts can selectively target CCA cells, 
influencing their neoplastic properties both in vitro and in vivo54. Conversely, tumor 
cells can release EVs that induce mesenchymal stem cells to change the local 
microenvironmental to enhance CCA cell growth55. A better understanding of such 
EV-mediated bidirectional interactions, and identification of the ncRNA species that 
are trafficked between tumor and stromal cells, could offer new CCA prevention 
strategies and/or therapeutic intervention in CCA patients. More importantly, the 
discovery that stroma-derived EVs are uniquely suited to deliver materials to CCA 
cells raises hope that EVs could be exploited to deliver anti-neoplastic therapies. For 
example, intravenous injection of miR-195-loaded fibroblast-derived EVs was shown 
to reach the tumor, decrease tumor size, and improve survival in a rat model of 
CCA56.  
 
 
Role of long ncRNAs in cholangiocarcinoma biology. 
Long non-coding RNAs (lncRNAs) are a subgroup of ncRNA transcripts that are 
longer than 200 nucleotides and not translated into proteins. Functions and 
mechanisms of action of lncRNAs are different from those of miRNAs and need 
further characterization. LncRNAs can regulate a myriad of biological processes 
through interaction with various cellular macromolecules such as DNA, RNA and 
proteins, acting either in the nucleus or in the cytoplasm. LncRNAs are involved in 
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the fine regulation of gene expression acting as epigenetic modifiers through 
recruitement of chromatin remodelling complexes to specific genomic loci, as 
enhancers in cis of neighbouring genes, and as scaffolds for the assembly of 
transcriptional regulatory molecules. LncRNA can affect several aspects of the post-
transcriptional regulation process, including mRNA stability, splicing, and translation. 
In addition, recent evidence suggests a role for lncRNAs and pseudogenes as 
sponges for small ncRNAs, behaving as cytoplasmic “controllers” of cell fate. 
Several studies have demonstrated that a number of lncRNAs play fundamental 
roles in a variety of pathological processes, including cancer57. lncRNA expression 
was found to be deregulated in human iCCA, with 2,773 up-regulated and 2,392 
down-regulated lncRNAs when compared to paired noncancerous tissue across a 
cohort of 77 human CCA patients29. Interestingly, these lncRNAs seem to regulate 
genes associated with cancer, hepatic system disease and signal transduction, 
supporting a role for lncRNAs in the development and progression of CCA. H19, the 
first lncRNA discovered, was found overexpressed in both CCA tissues and CCA cell 
lines, where it contributes to different steps in cholangiocarcinogenesis by promoting 
cell proliferation, migration, invasion, evasion of apoptosis, and EMT58. Similar 
oncogenic properties were reported for other lncRNAs such as AFAP1 antisense 
RNA 1 (AFAP1-AS1)59, CPS1 intronic transcript 1 (CPS1-IT1)60 metastasis 
associated lung adenocarcinoma transcript 1 (MALAT1), promoter Of CDKN1A 
antisense DNA damage activated RNA (PANDAR), prostate cancer associated 
transcript 1 (PCAT1), colon cancer associated transcript 1 (CCAT1), taurine up-
regulated 1 (TUG1), urothelial cancer associated 1 (UCA1), and SOX2 overlapping 
transcript (SOX2-OT)61-65. lncRNAs are also involved in sustaining CCA progression 
induced by inflammation. For example, H19 and HULC are induced by oxidative 
stress and can deregulate the cellular host inflammatory response by acting on 
genes such as IL-6 and C-X-C motif chemokine receptor 4 (CXCR4)66. 
Ultraconserved regions (UCRs) are non-coding genomic segments >200 nucleotides 
in length that are remarkably conserved beween species, with 100% sequence 
similarity across the human, mouse, and rat genomes. The deregulation of UCR 
transcription has been increasingly implicated in human cancers. It has been 
postulated that the conservation of UCR gene sequences between species indicates 
that UCRs have an essential functional role, suggesting that an alteration in their 
transcription may represent the first step in malignant transformation. Transcripts 
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derived from UCRs may be of various lengths, and their 3D structure is likely to 
impact on their function by affecting their interaction with ribonucleoproteins or their 
ability to capture small ncRNAs in “sponge-like” structures67-68. We and others 
showed that the deregulation of transcribed-UCR (T-UCR) occurs in the cancer 
tissues but is already present in the adjacent background tissue, suggesting that it 
may create a favorable environment for the progression of cancer67,69. Furthermore, 
we have shown that uc.158-can act downstream of the Wnt pathway and is likely to 
represent the cellular mediator that promotes CCA cell growth in response to stroma-
derived Wnt signaling. More recently, lncRNAs can differentiate between T-cell 
classes more precisely than mRNAs, suggesting lncRNAs are potential drivers of 
immune cell fate and regulators of the interplay between cancer cells and those in 
the microenvironment70. 
 
 
Clinical implications of ncRNAs in cholangiocarcinoma 
In addition to acting within cells, miRNAs are released and circulate in serum, 
plasma, and other bodily fluids, either as free RNAs bound to the argonaut RNA-
induced silencing complex (RISC) catalytic component or in extracellular vesicles, 
such as exosomes or microvesicles71. This protects miRNAs from degradation via 
RNAses and gives them stability and resistance during the storage and handling of 
patient samples. All of these properties, together with the ability to isolate, 
characterize and identify disease-specific miRNA content in tissues and bodily fluids, 
has raised interest in miRNAs as a gold mine of biomarkers with potential in cancer 
diagnosis, prognosis, treatment response, and therapy72 (Table 3). 
 
Diagnostic role 
CCA diagnosis is often challenging due to the lack of specific symptoms, the 
technical difficulty  to access tissue, and the intense stroma reaction and 
paucicellular neoplastic nature of this disease. Thus, there is an urgent need for 
diagnostic tools that can enable early cancer detection. The pattern of miRNA 
expression in CCA cell lines and human tissues significantly differs from that in non-
malignant counterparts, suggesting that CCA-specific miRNA expression profiles 
could be used to develop diagnostic assays. Differentiating between CCA and 
benign disorders harboring biliary strictures (e.g. PSC) poses a particular challenge 
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since they appear the same when imaged and because of the difficulties associated 
with obtaining cytological and/or histological samples of sufficient yield73. A 
combination of two circulating miRNAs (miR-222 and miR-483-5p) in the serum were 
proven to differentiate CCA patients from PSC patients in a retrospective study 
including a discovery (n=90) and a validation cohort (n=140)74, showing the promise 
of circulating miRNAs. Additional experiences showed a good negative predictive 
value for circulating miRNA signatures that were able to correctly identify 12 out of 
13 patients with PSC who did not develop CCA75. However, circulating miRNAs in 
the blood are known to be affected by other conditions, such as liver injury, 
cardiovascular disease, sepsis and immunological disorders, and therefore the use 
of circulating miRNAs should be applied with caution in the clinical practice in view of 
their limited positive predictive value. A way to overcome this issue is to search for 
CCA-specific miRNAs in the bile. Owing to the direct contact, diagnostic information 
could be obtained in the bile where tumor-related biomarkers may have increased 
concentrations and conversely non-tumor markers may be less represented72. 
Moreover, an increasing number of studies have shown that the EVs released into 
the bile of individuals affected by liver disease differ in functional content to those 
found in the bile of healthy individuals. Li et al. provided the first evidence that 
human bile contains miRNA-laden EVs76, thus paving the way for the exploitation of 
their biomarker potential in biliary tract diseases. Using a multivariate combinatorial 
model, researchers were able to define a novel bile-based 5-miRNA panel (miR-191, 
miR-486-3p, miR-1274b, miR-16 and miR484) for CCA diagnosis that had 67% 
sensitivity and 96% specificity. Notably, this diagnostic tool was more accurate than 
the commonly available standard methods used in clinical practice (e.g. CA19-9). 
More interestingly, of the 11 CCA patients correctly diagnosed by the 5-miRNA 
panel, but misdiagnosed by CA19-9, 8 had early-stage disease (N0M0), underlining 
the potential of this miRNA signature approach to detect cancers in its early stages. 
It is worth remembering that CCA is endemic in some areas of north-eastern 
Thailand, where the implementation of a screening program could significantly 
impact on CCA-induced mortality. However, liver-fluke induced CCA has a different 
genetic and transcriptomic background to the CCA that arises in the western world77. 
Thus, it is likely that a miRNA-based diagnostic biomarker for CCA should be 
specifically targeted to this population limiting the potential of extending studies on 
Western populations to Eastern populations. The use of urine-based biomarkers is 
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likely to be implemented more successfully in screening programs than those based 
on the profile of miRNAs in other bodily fluids. MicroRNAs can be detected in the 
urine given they are filtered through the renal system due to their small size and their 
high stability. Silakit and coworkers have reported that miR-192 is significantly higher 
in the urines of O. viverrini-infected subjects in comparison to healthy subjects with a 
sensitivity of 75.0% and a specificity of 71.4%78. Although good, these values are not 
high enough to be applied to screening programs, and therefore more work is 
needed. The measurement of more than one miRNA is likely to represent the best 
approach for increasing the accuracy of the test. For example, the addition of urinary 
miR-21 to miR-192 resulted in a test sensitivity of 79.2%  and a specificity of 76.2%, 
when attempting to distinguish O. viverrini-infected subjects from healthy ones. 
However, it is worthy mentioning that miR-21 is increased in a variety of tumours and 
non malignant diseases and lacks specificity as a diagnostic marker. 
CCA is a disease with unique diagnostic challenges, the detection of dysregulated 
miRNAs into accessible biofluids in patients harboring a high index of suspicion for 
CCA offers an opportunity for earlier diagnosis and thus higher chances of curability. 
However, several issues remain to be addressed. Specimen collection and 
manipulation must be standardized in order to derive a test that can be applied in a 
prospective fashion. We believe that the levels of circulating miRNAs should not be 
normalized to those of reference transcripts (or miRNAs), as a direct count of the 
miRNA molecules in a given volume of biofluid is likely to represent the most 
accurate method for clinical implementation. The advancement in technologies with 
the introduction of digital PCR and RNA-sequencing should render it possible to 
directly count such molecules and identify a threshold that can be applied for 
prospective validation. However, it is certain that large patient cohorts are needed to 
investigate the distribution of circulating miRNAs in the population at risk, and to 
understand their association with CCA development in a manner that is independent 
of other comorbidities. In tumors with a low prevalence, such as CCA, this goal can 
only be achieved through a collaborative international effort. We can speculate that 
the detection of miRNAs within CCA-specific EVs can improve diagnostic accuracy, 
and that the ongoing efforts to extensively characterize EVs will identify markers 
enriched in CCA-specific EVs to achieve this goal 79-80 (and their ncRNA content). A 
more provocative question could be: “Do we need to identify a miRNA that is cancer-
specific to improve early diagnosis and promote prevention?”. We have learnt from 
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the latest advances in oncology that the host immune response plays a driving role 
in containing and attacking cancer, enabling the “defeat” of cancer even in cases of 
multi-metastatic disease81-83. It is reasonable to speculate that the immune system is 
playing even a more important role in the early stages of malignant transformation 
and that detecting markers that are indicative of the failure of the host immune 
response may be informative for early diagnosis. Given the evidence that ncRNAs 
can drive the fate of immune cells and their function70, it may be useful to start 
looking for changes in ncRNAs that reflect a poor immunological response rather 
than the presence of a cancer that has already developed.  
  
Prognostic role 
Based on the identification of ncRNAs as drivers of CCA progression, growing 
research efforts are attempting to identify CCA-related miRNA signatures that could 
inform disease prognosis and patient selection. In a cohort of 84 patients with iCCA, 
high expression of miR-191 was found to be independently associated with worse 
disease-free survival  and OS84. miR-21 has also been consistently found to be 
associated with adverse clinicopathological features and survival85. More 
interestingly, circulating miR-21 levels dropped in patients undergoing curative 
surgery, but not in those receiving palliative resection, suggesting that the levels of 
miR-21 in the plasma reflect the extent of the tumor and can be used as a surrogate 
marker for prognosis. Likewise, high serum miR-26a expression has been 
significantly correlated with clinical stage, distant metastasis, differentiation status, 
and the poor survival of CCA patients86. Looking for highly-expressed miRNAs may 
be less technically challenging than looking for down-regulated miRNAs, where 
absence or low levels can also be associated with technical failure. However, recent 
evidence support a prognostic role for low tissue levels of miR-203, a tumor 
suppressor miRNA, in resected CCA87. With the introduction of adjuvant 
chemotherapy in the management of resected CCA, the discovery of a prognostic 
marker may represent a valuable asset for identifying those patients who are most 
likely to benefit from post-operative treatment. In this regard, it is likely that the study 
of tissue and circulating (where possible) miRNAs, in large cohorts in prospective 
clinical trials, will offer more insight than the investigation of the clinical value of 
ncRNAs in small retrospective series. The availability of tissue from resected tumors 
in this setting offers an additional opportunity for ncRNA detection by employing in 
14 
 
situ technologies that enable a semi-quantitative score that can be easily 
implemented in the clinic. We and others have previoulsy shown that cancer can be 
classified on the basis of ncRNA expression measured using in situ hybridization 
techniques in formalin-fixed paraffin-embedded tissue, and scored following the 
methods used for immunohistochemistry68,88. 
  
Predictive role 
Chemotherapy still represents the mainstay of advanced CCA treatment, while 
targeted agents and immunotherapy have shown potential in selected patient 
populations9,89-90. Active chemotherapy regimens include gemcitabine, capecitabine, 
a combination of cisplatin and gemcitabine (CG) or of fluorouracil and oxaliplatin 
(FOLFOX)11,91-92 . With an increasing number of treatment options on the horizon, 
the need for personalized medicine is emerging. However, the window of opportunity 
for treatment in CCA patients is limited, because of the rapid deterioration in patients’ 
fitness upon chemotherapy failure. Indeed, while some patients that fail to respond to 
first line chemotherapy may still be sensitive to second line options a rapid drop in 
their performance status might preclude further lines of therapy. A better 
understanding of the mechanisms underpinning chemo-resistance will improve 
patient selection and provide important tools to enable decision-making in regard to 
the choice of chemotherapy sequence, achieving rapid disease control in responders 
and minimizing the risk of unnecessary toxicity in patients who are unlikely to benefit. 
Aberrantly-expressed miRNAs in cancer cells are thought to regulate the expression 
of genes critical for cell survival in response to chemotherapeutic stress. For 
instance, miR-21 expression was shown to increase following exposure to cytotoxic 
drugs and to modulate gemcitabine-induced apoptosis by phosphatase and tensin 
homolog (PTEN)-dependent activation of PI3-kinase signaling in in vitro and in vivo 
models24. In other reports, the loss of selected miRNAs (miR-29, miR-320, and miR-
204) was found to mediate the resistance of CCA cells to chemotherapeutics, by 
acting on the apoptotic pathway93-94. Although preclinical, these observations link 
ncRNAs with the sensitivity of tumor cells to chemotherapy and suggest that ncRNAs 
should be investigated in the translational component of large clinical trials. The 
possibility of detecting circulating miRNAs in the blood of CCA patients increases the 
applicability of such tests in the advanced disease setting where tissue availability is 
limited. In addition, as described above, circulating miRNAs can be affected by other 
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comorbidities and thus have the potential to represent surrogate markers of the 
general medical status of the patient, information on which treatment choice can be 
based.  
miRNAs can drive a number of cellular processes, and therefore have the potential 
to modulate cell sensitivity to a number of non-chemotherapy drugs. We, and others, 
have recently proven that heat shock protein 90 (HSP90) inhibition can be a 
promising therapeutic strategy in CCA95-96. The HSP90 complex interacts with a 
variety of client proteins which have a key role in CCA progression, such as 
epidermal growth factor receptor (EGFR), phosphoinositide-3-kinase, PTEN, human 
epidermal growth factor receptor 2, human epidermal growth factor receptor 3, and 
phosphoribulokinase A. Moreover, inhibition of HSP90 seems to be remarkably 
effective in tumors with fibroblast growth factor receptor fusions and activation of the 
IL-6/STAT pathway97-98. HSP90 controls the post-translational folding of argonaute2 
(AGO2), a regulator of miRNA processing99, suggesting that miRNAs could 
represent good biomarker candidates. We have shown that miR-21 can drive 
resistance to HSP90 inhibition by specifically affecting the multi-chaperone complex 
in a way that is recapitulated in human CCA cell lines, 3D organoid structures and 
patient-derived xenografts95. Given the potential of miRNAs to affect a range of 
signaling pathways, we suggest to include ncRNAs within future drug discovery 
projects expanding our pivotal experience. Patient-derived organoids (PDO) are 
organotypic cultures that recapitulate the architecture, genomic- and transcriptomic-
profile of human tumors, and mimic their treatment response in the clinic, holding 
great potential in advancing drug discovery projects. We recently provided evidence 
that PDOs can be established from tissue derived from advanced CCA patients and 
can be manipulated to change miRNA expression, opening the way for the use of 
PDOs as a tool to personalize medicine and apply functional genomics to identify the 
involvement of ncRNAs in the response to drugs in CCA95. 
  
ncRNA-based therapeutics 
Insights into the role of ncRNAs in tumor biology, alongside their ability to target 
multiple genes and signaling pathways simultaneously, have made them attractive 
targets and therapeutic tools for novel anti-cancer approaches. The two main 
strategies for modulating miRNA expression are based on the introduction of 
synthetically-derived small RNA duplexes that behave similarly to endogenous 
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miRNAs (miRNA mimics) or, conversely, on the delivery of molecules targeted at 
miRNAs (anti-miRNAs or miRNAs inhibitors). In the former case, the aim is to 
replenish the lost expression of miRNAs acting as tumour suppressor, whereas in 
the latter case the aim is to oppose the function of oncogenic miRNAs100. In both 
cases, appropriate target selection as well as strategies for tissue/cancer-specific in 
vivo delivery are critical steps in order to pursue the therapeutic goal while 
minimizing off-target effects and toxicities. The identification of the best miRNA 
targets is challenging, mainly because no miRNAs are entirely cancer-specific and 
conditions such as inflammation and hypoxia can affect miRNA expression, 
complicating the search for candidate miRNAs101. Moreover, the concept of temporal 
and spatial heterogeneity applies also to miRNAs, whose expression is dynamic over 
time and may vary intertumorally and intratumorally. Among the strategies being 
used to select key regulatory miRNAs is miRNA crosslinking and 
immunoprecipitation (miR-CLIP), a novel technique that can identify relevant miRNA 
pathways by capturing their putative targets, the so-called “targetome”102. The 
matching of these data or other from public repositories on miRNA interaction 
networks with prediction platforms will allow for a more accurate identification of best 
candidate miRNAs to be targeted. An additional strategy to look for key regulatory 
miRNAs is based on genome-wide high-throughput-screening technologies to 
evaluate libraries of miRNA mimics or inhibitors.  
The degradation of naked particles by nucleases is a key issue which needs to be 
overcome before implementing miRNA-based therapeutics. To optimize the delivery 
of miRNA mimics/anti-miRNAs their nucleotide backbone can be chemically modified 
to improve their stability in bodily fluids and prevent degradation in serum and 
endocytic cellular compartments. However, oligonucleotide methylation, the 
introduction of locked nucleic acids, or the addition of phosphorothioate-like groups 
can result not only in an increase in miRNA stability but also in the loss of mRNA 
silencing, or in off-target effects and the production of toxic metabolites. The ideal 
delivery vehicle would be a non-immunogenic and biodegradable carrier, displaying 
target tumor specificity and robust binding. One of the most successful approaches 
is to encapsulate the miRNA mimics/anti-miRNAs into nanoparticles. Poly(lactide-co-
glycolide) particles, neutral lipid emulsions, neutral liposome 1,2-dioleoyl-sn-glycero-
3-phosphatidylcholine, polyethylenimine, polyethylene glycol, chitosan and n-acetyl-
d-galactosamine are all promising platforms for miRNA therapeutics delivery that are 
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currently being tested in clinical trials. However, both the efficiency with which 
miRNA mimics/anti-miRNAs are delivered to the target site and their safety profile 
are still suboptimal, partly as a result of the net cationic charge of the carriers.  
The strategy of replenishing miRNAs with tumor-suppressive function in vivo has 
recently been pursued in humans. Van Zandwijk et al. reported the results of the 
first-in-man phase 1 trial with a miR-16 mimic, which was administered to patients 
with recurrent malignant pleural mesothelioma103. Minicells loaded with a miR-16-
based miRNA mimic and targeted to EGFR (TargomiRs) were administered to 26 
patients with EGFR immunohistochemical expression that had disease progression 
after receiving standard chemotherapy. TargomiRs were given over a 20 minutes 
intravenous infusion either once or twice weekly according to a traditional 3+3 dose-
escalation design across 5 dose cohorts. Among 22 assessable patients, one (5%) 
had a partial response and 15 (68%) had stable disease. These encouraging data 
show how the delivery of miRNA mimics can be a clinically feasible and effective 
approach. However, toxicity concerns remain, as in this study the TargomiR induced 
cardiotoxicity in 5 patients. The exact mechanism responsible for the cardiological 
toxicity is still not clear, as it may be a direct effect of the miRNA itself or the 
consequence of the inflammatory reaction induced by the minicell delivery vehicle. 
Advances in technology are likely to yield safer delivery methods, which can 
increase efficacy and reduce the toxicity associated with this therapeutic strategy. 
Moreover, pharmacological studies and the assessment of miRNA in the tumour 
tissue after administration of the miRNA-based therapeutics should be included in 
future studies to better understand the dynamics of the systemic delivery of these 
new therapeutics. On a different standpoint, targeting of miR-122 proved successfull 
in a phase 2a trial in patients with chronic HCV genotype 1 infection104. A 15-
nucleotide locked nucleic acid-modified DNA phosphorothioate antisense 
oligonucleotide (Miravirsen) was given in a random fashion to 36 patients, who had 
been subdivided into 4 groups and given doses of 3, 5 or 7 mg per kg, or a placebo, 
over a 29 day period. Prolonged dose-dependent reductions in HCV RNA levels 
were observed, with no dose-limiting toxicities, no evidence of viral resistance or 
occurence of hepatocellular carcinoma. With regards to liver tumors, MRX34, a 
liposomal miR-34 mimic, has been the first miRNA mimic to enter clinical evaluation 
in patients with solid tumors, including hepatocellular carcinoma105. In this phase I, 
first-in-human, dose-escalation study, MRX34 was administered intravenously 
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biweekly or daily (x 5 days) to 99 patients with advanced solid tumors. MRX34 had a 
manageable safety profile, as the most commonly reported adverse events were 
mild in grade (fever, chills, fatigue, back pain, nausea), with grade 3 
lymphocytopenia, thrombocytopenia, elevated AST, neutropenia, and hyponatremia 
as the more frequent laboratory abnormalities. This liposomal miR-34 mimic 
displayed anticancer activity, achieving a prolonged confirmed RECIST partial 
response in 3 patients (one of whom had hepatocellular carcinoma), and stable 
disease in 14 other cases. A phase Ia expansion cohorts is currently underway and 
phase II studies are being planned (Clinical trial information: NCT01829971). Recent 
preclinical evidence showed that this miR34 mimic can also suppress the growth of 
CCA cells106, suggesting that this investigation could be extended to CCA patients. 
  
 
Conclusion 
CCA is characterized by late diagnosis and poor response to standard treatment 
resulting in an almost invariably dismal prognosis. Therefore, there is an urgent need 
for earlier diagnosis, a better prediction for tumor aggressiveness and response to 
treatment as well as novel therapeutic options. The better understanding of CCA 
biology has revealed ncRNAs as pivotal players affecting CCA initiation, progression 
and treatment resistance. On these premises, ncRNAs are being studied intensively 
as promising tumor biomarkers to incorporate in the clinical management for 
improving the outcome of CCA patients. Preliminary findings are encouraging, even 
though further research is required to confirm their reliability and clinical 
reproducibility. 
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Figure legend 
 
Figure 1. Selected ncRNAs interacting with their relative targets within major 
oncogenic signaling pathways altered in CCA. Upwards black arrow shows 
upregulated ncRNAs, while downwards black arrow refers to downregulated 
ncRNAs. Continous arrows shows an activating function, while dashed line refers to 
inhibitory function. 
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